Gul Sania, Sridhar Sathvik Belagodu, Jalil Aamir, Akhlaq Muhammad, Arshad Muhammad Sohail, Sarwar Hafiz Shoaib, Usman Faisal, Shareef Javedh, Thomas Sabin
Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras al Khaimah 11172, United Arab Emirates.
Pharmaceuticals (Basel). 2024 Apr 14;17(4):500. doi: 10.3390/ph17040500.
Liquid self-nano emulsifying drug delivery systems (SNEDDS) of furosemide (FSM) have been explored as a potential solution for enhancing solubility and permeability but are associated with rapid emulsification, spontaneous drug release, and poor in vivo correlation. To overcome the shortcoming, this study aimed to develop liquid and solid self-emulsifying drug delivery systems for FSM, compare formulation dynamics, continue in vivo therapeutic efficacy, and investigate the advantages of solidification. For this purpose, liquid SNEDDS (L-SEDDS-FSM) were formed using oleic acid as an oil, chremophore EL, Tween 80, Tween 20 as a surfactant, and PEG 400 as a co-surfactant containing 53 mg/mL FSM. At the same time, solid SNEDDS (S-SEDDS-FSM) was developed by adsorbing liquid SNEDDS onto microcrystalline cellulose in a 1:1 ratio. Both formulations were evaluated for size, zeta potential, lipase degradation, and drug release. Moreover, in vivo diuretic studies regarding urine volume were carried out in mice to investigate the therapeutic responses of liquid and solid SNEDDS formulations. After dilution, L-SEDDS-FSM showed a mean droplet size of 115 ± 4.5 nm, while S-SEDDS-FSM depicted 116 ± 2.6 nm and zeta potentials of -5.4 ± 0.55 and -6.22 ± 1.2, respectively. S-SEDDS-FSM showed 1.8-fold reduced degradation by lipase enzymes in comparison to L-SEDDS-FSM. S-SEDDS-FSM demonstrated a sustained drug release pattern, releasing 63% of the drug over 180 min, in contrast to L-SEDDS-FSM, exhibiting 90% spontaneous drug release within 30 min. L-SEDDS-FSM exhibited a rapid upsurge in urine output (1550 ± 56 μL) compared to S-SEDDS-FSM, showing gradual urine output (969 ± 29 μL) till the 4th h of the study, providing sustained urine output yet a predictable therapeutic response. The solidification of SNEDDS effectively addresses challenges associated with spontaneous drug release and precipitation observed in liquid SNEDDS, highlighting the potential benefits of solid SNEDDS in improving the therapeutic response of furosemide.
速尿(FSM)的液体自纳米乳化药物递送系统(SNEDDS)已被探索作为提高溶解度和渗透性的潜在解决方案,但存在快速乳化、药物自发释放以及体内相关性差的问题。为克服这些缺点,本研究旨在开发FSM的液体和固体自乳化药物递送系统,比较制剂动力学,延续体内治疗效果,并研究固化的优势。为此,使用油酸作为油相,聚氧乙烯蓖麻油EL、吐温80、吐温20作为表面活性剂,聚乙二醇400作为助表面活性剂,制备含53mg/mL FSM的液体SNEDDS(L-SEDDS-FSM)。同时,通过将液体SNEDDS以1:1的比例吸附到微晶纤维素上,开发出固体SNEDDS(S-SEDDS-FSM)。对两种制剂的粒径、zeta电位、脂肪酶降解和药物释放进行了评估。此外,在小鼠中进行了关于尿量的体内利尿研究,以研究液体和固体SNEDDS制剂的治疗反应。稀释后,L-SEDDS-FSM的平均液滴尺寸为115±4.5nm,而S-SEDDS-FSM为116±2.6nm,zeta电位分别为-5.4±0.55和-6.22±1.2。与L-SEDDS-FSM相比,S-SEDDS-FSM被脂肪酶降解的程度降低了1.8倍。S-SEDDS-FSM呈现出持续的药物释放模式,在180分钟内释放63%的药物,相比之下,L-SEDDS-FSM在30分钟内自发释放90%的药物。与S-SEDDS-FSM相比,L-SEDDS-FSM的尿量迅速增加(1550±56μL),在研究的第4小时显示出逐渐增加的尿量(969±29μL),提供持续的尿量但有可预测的治疗反应。SNEDDS的固化有效地解决了液体SNEDDS中观察到的与药物自发释放和沉淀相关的挑战,突出了固体SNEDDS在改善速尿治疗反应方面的潜在益处。